Effectiveness of a checklist for the control of the disease activity in patients with axial spondyloarthritis

IF 1.3 Q4 RHEUMATOLOGY

Reumatologia Clinica Pub Date : 2025-08-01 DOI:10.1016/j.reuma.2025.501918

Raquel Almodóvar , Elia Pérez-Fernández , Marta Valero , Virginia Villaverde , Laura González , Beatriz Joven Ibáñez , Eva Tomero Muriel , Alejandro Prada Ojeda , M.a Teresa Navio , Laura Cebrián Méndez , Leticia Lojo , Ramón Mazzucchelli , Pedro Zarco Montejo

{"title":"Effectiveness of a checklist for the control of the disease activity in patients with axial spondyloarthritis","authors":"Raquel Almodóvar , Elia Pérez-Fernández , Marta Valero , Virginia Villaverde , Laura González , Beatriz Joven Ibáñez , Eva Tomero Muriel , Alejandro Prada Ojeda , M.a Teresa Navio , Laura Cebrián Méndez , Leticia Lojo , Ramón Mazzucchelli , Pedro Zarco Montejo","doi":"10.1016/j.reuma.2025.501918","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><div>To assess the effectiveness of a checklist for disease activity and comorbidity control in patients with axial spondyloarthritis (axSpA).</div></div><div><h3>Method</h3><div>A quasi-experimental retrospective multicentre pre-post intervention study was carried out in Spain between 2016 and 2022. Improvement in disease activity and comorbidity status was determined before and after the implementation of a checklist control in patients diagnosed with axSpA. Disease activity was determined by means of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and C-reactive protein (CRP) levels. Comorbidity status was determined by analysing several risk factors (blood pressure, body weight, blood test, etc.). An analysis of variance with mixed models between pre and post collected values was performed. The change in therapeutic level and disease status (low activity, remission) was determined by means of the Mc-Nemar asymmetry test.</div></div><div><h3>Results</h3><div><span><span>A total of 108 patients with axSpA were included in the study. After checklist implementation, a statistically significant reduction in </span>BASDAI of 0.44 (95%CI: 0.06–0.82, </span><em>p</em>   =0.001) in CRP was observed. Besides, an increase in uricemia of 0.24mg/dl was found (95%CI: 1.49–6.14, <em>p</em>  <!-->0.001), while no other statistically significant change in comorbidities was observed.</div></div><div><h3>Conclusions</h3><div>The implementation of a checklist in daily clinical practice leads to a significant improvement in the control of disease activity in patients with axSpA.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 7","pages":"Article 501918"},"PeriodicalIF":1.3000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Reumatologia Clinica","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1699258X25001123","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives

To assess the effectiveness of a checklist for disease activity and comorbidity control in patients with axial spondyloarthritis (axSpA).

Method

A quasi-experimental retrospective multicentre pre-post intervention study was carried out in Spain between 2016 and 2022. Improvement in disease activity and comorbidity status was determined before and after the implementation of a checklist control in patients diagnosed with axSpA. Disease activity was determined by means of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and C-reactive protein (CRP) levels. Comorbidity status was determined by analysing several risk factors (blood pressure, body weight, blood test, etc.). An analysis of variance with mixed models between pre and post collected values was performed. The change in therapeutic level and disease status (low activity, remission) was determined by means of the Mc-Nemar asymmetry test.

Results

A total of 108 patients with axSpA were included in the study. After checklist implementation, a statistically significant reduction in BASDAI of 0.44 (95%CI: 0.06–0.82, p = 0.023) and a significant reduction of 3.82 mg/L (p = 0.001) in CRP was observed. Besides, an increase in uricemia of 0.24 mg/dl was found (95%CI: 1.49–6.14, p = 0.001), while no other statistically significant change in comorbidities was observed.

Conclusions

The implementation of a checklist in daily clinical practice leads to a significant improvement in the control of disease activity in patients with axSpA.

查看原文本刊更多论文

检查表对控制轴性脊柱炎患者疾病活动的有效性

目的评估轴性脊柱炎（axSpA）患者疾病活动性和合并症控制检查表的有效性。方法2016 - 2022年在西班牙开展准实验回顾性多中心干预前后研究。在诊断为axSpA的患者实施检查表对照前后，确定疾病活动性和合并症状态的改善。采用巴斯强直性脊柱炎疾病活动性指数（BASDAI）和c反应蛋白（CRP）水平测定疾病活动性。通过分析几个危险因素（血压、体重、血液检查等）确定合并症状况。使用混合模型对采集前后的数据进行方差分析。通过Mc-Nemar不对称检验确定治疗水平和疾病状态（低活动，缓解）的变化。结果共纳入108例axSpA患者。实施检查表后，BASDAI显著降低0.44 (95%CI: 0.06-0.82, p = 0.023)， CRP显著降低3.82 mg/L （p = 0.001）。此外，尿毒症增加0.24 mg/dl (95%CI: 1.49 ~ 6.14, p = 0.001)，而其他合并症无统计学意义的变化。结论在日常临床实践中实施检查表可显著改善axSpA患者疾病活动的控制。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Reumatologia Clinica RHEUMATOLOGY-

CiteScore

2.40

自引率

6.70%

发文量

105

审稿时长

54 days

期刊介绍： Una gran revista para cubrir eficazmente las necesidades de conocimientos en una patología de etiología, expresividad clínica y tratamiento tan amplios. Además es La Publicación Oficial de la Sociedad Española de Reumatología y del Colegio Mexicano de Reumatología y está incluida en los más prestigiosos índices de referencia en medicina.